Summary
This Spanish-language review examines the clinical evidence and controversies surrounding growth hormone treatment in Prader-Willi syndrome, approved in Europe since 2001. Whilst GH treatment aims to improve body composition, muscle strength and cognitive capacity beyond height gain alone, the paper suggests uncertainty persists about genuine clinical benefits and safety risks, which partly limits systematic treatment uptake. The review synthesises published evidence to address these unresolved questions in paediatric endocrinology practice.
UK applicability
UK paediatric endocrinologists follow similar European regulatory frameworks for GH use in Prader-Willi syndrome. The evidence synthesis may inform clinical decision-making within NHS paediatric services, though UK-specific guideline alignment would require consultation of parallel British and NICE literature.
Key measures
Final height, body composition, muscle strength, cognitive function, adverse events in Prader-Willi syndrome patients receiving GH treatment
Outcomes reported
The study reviewed evidence on growth hormone (GH) treatment in Prader-Willi syndrome patients, examining both clinical benefits (final height, body composition, muscle strength, cognitive capacity) and potential adverse effects. The review addresses controversies surrounding GH use and barriers to systematic treatment access in eligible patients.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.